Illumina, Inc. vs MINISO Group Holding Ltd — how do they compare? Illumina, Inc. trades at $265 (market cap $40.43B), while MINISO Group Holding Ltd trades at $9.17 (market cap $2.59B). The key difference: Illumina, Inc. is far larger — about 15.6× MINISO Group Holding Ltd's market cap, and MINISO Group Holding Ltd pays a 7.45% dividend while Illumina, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold Illumina, Inc. for 83 Days and MINISO Group Holding Ltd for 24 Days on average.
| ILMN | MNSO | |
|---|---|---|
Market Cap | $40.43B | $2.59B |
Volume | 2,948,626 | 685,013 |
Sector | Health | Consumer Cyclical |
52-Week High | $293.69 | $22.75 |
52-Week Low | $91.00 | $8.60 |
Typical Hold Time | 83 Days | 24 Days |
Enterprise Value | $41.79B | $3.46B |
Dividend Yield | — | 7.45% |
Signals from Pluang's Aura AI — not financial advice
Illumina (ILMN) trades at $264.40, down 3.34% on the day but up significantly year-to-date with strong technical momentum. The stock shows bullish moving average signals and trades near pivot point resistance at $268. Fundamentally, the company has delivered three consecutive quarterly earnings beats and returned to profitability in 2025 with $850 million net income after previous losses. Recent catalysts include S&P 500 inclusion effective September 21, 2026, and growing AI integration in genomics applications.
The outlook remains positive with analyst consensus favoring Buy ratings (54%) and a $241 price target, though current price exceeds consensus. Key opportunities include sequencing growth and AI-driven biological data expansion, while risks involve China market headwinds and elevated valuation multiples. Earnings growth and S&P 500 inclusion provide near-term catalysts, but the stock trades at premium valuations with P/E of 49.96 requiring sustained execution.
MNSO trades at $8.94, up 0.34% on the day, with a bearish technical signal from moving averages. The company reported mixed quarterly earnings, missing estimates in three of the last four quarters but beating in Q1 2026. Revenue grew to $21.44 billion in 2025, with a net income margin of 5.35%. Analyst sentiment is mixed with a 60% buy rating, while recent news highlights CFO share purchases and a 52-week low.
The outlook for MNSO hinges on improving earnings consistency and margin stabilization. Investment opportunities include attractive valuation multiples like a P/E of 14.55 and P/S of 0.78, but risks involve volatile earnings, overseas margin pressures, and competitive retail dynamics. The stock's recent decline to near 52-week lows may present a value entry if operational improvements materialize.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (less than 10% of sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
Read more on ILMN →MINISO Group Holding Ltd is a global lifestyle product retailer known for its aesthetically pleasing, high-quality, and low-cost goods. The company operates a network of branded stores worldwide, offering a diverse range of merchandise, including household goods, cosmetics, toys, and digital accessories. MINISO's business model emphasizes rapid product iteration, efficient supply chain management, and a joint venture and franchise partner network to facilitate its global expansion.
Read more on MNSO →